中药中药“十九畏”的历史源流、宜忌争论与思考建议  

The historical evolution,incompatibility arguments and suggestions on nineteen antagonisms medicaments

作　　者：欧丽娜[1,2] 钟赣生[1] 柳海艳[1] 陈绍红[1] 张建美[1] 

机构地区：[1]北京中医药大学基础医学院,北京100029 [2]河南科技大学医学院,洛阳471003

出　　处：《科技导报》2016年第11期31-36,共6页Science & Technology Review

基　　金：国家自然科学基金项目(81573630)

摘　　要：通过分析"十九畏"的历史沿革及研究现状,提出下一步开展"十九畏"研究的建议。回顾了"相畏"的含义衍变、"十九畏"歌诀的出现、目前《中国药典》对"十九畏"的相关规定。从文献记载、临床报道、实验研究3个方面论述了关于"十九畏"的宜忌争论。分析整理文献,总结"十九畏"在临床研究和实验研究方面的进展,可以看出,临床方面的研究多是从文献的角度,进行回顾性总结,从中挖掘整理"十九畏"反药组合的临床安全性评价和配伍应用规律。关于"十九畏"的实验研究主要从化学物质基础、药理学、毒理学几方面开展。总结了关于"十九畏"研究存在的问题,并提出对"十九畏"今后研究工作的相关建议。Through the analyses of the history and the present situation of nineteen antagonisms, the paper puts forward suggestions for the study of nineteen antagonisms. The development of the conception of ＂incompatibility＂, the suggestions of nineteen antagonisms, as well as the relevant provisions about nineteen antagonisms in Pharmacopoeia of People＇s Republic of China are reviewed. The incompatible arguments of nineteen antagonisms in the ancient literature, the experimental study and clinical reports are discussed. It can be seen that the clinical study always concerns the clinical reports, and then analyzes and proposes the clinical safety evaluation and the rules of the compatible application of nineteen antagonisms. While the experimental study on nineteen antagonisms mostly concerns the aspects of the chemical material foundation, the pharmacology and toxicology studies. We summarizes the existing problems in the studies of nineteen antagonisms, and put forward some suggestions, to provide some guidance for the future researches.

关 键 词：中药配伍禁忌 十九畏 历史沿革 宜忌争论 

分 类 号：R289.1[医药卫生—方剂学]